Francis C. Brown

Francis C. Brown is the most improbable figure in the history of the modern American pharmaceutical industry: a New Deal lawyer with no science, no chemistry, and no prior experience in medicine, who in 1943 found himself running a confiscated enemy-owned drug company, and spent the next twenty-three years building it into a research powerhouse ^[4][5]. Schering Corporation had begun as the New York and New Jersey arm of Schering AG of Berlin, a German pharmaceutical and hormone house founded by Ernst Schering in 1851 ^[1][6]. When the United States entered the war, the German parent's American shares were vested in the U.S. Alien Property Custodian on April 18, 1942, and the German managers were ousted from the premises ^[3]. The government needed someone to run the orphaned company. It chose Brown ^[4].

Brown had no obvious qualification for the job except trust. He had been a New Deal lawyer who joined the Federal Deposit Insurance Corporation in the 1930s and served as legal counsel to Leo T. Crowley, and when Crowley was named Alien Property Custodian, he handed his lawyer the keys to Schering ^[4][5]. Brown filled the vacant executive offices with associates from the FDIC and, in 1943, was formally appointed president of the company he had been sent merely to caretake ^[4]. He would, as the federal courts later recorded, "in fact remain in the post through October 1966", outlasting the war, the government's ownership, and the company's sale to private investors ^[2].

What Brown grasped, with the clarity of an outsider, was that a drug company lives or dies on what comes out of its laboratories. "Brown realized that research and development was the key to success in the pharmaceutical industry," the company's own history records, and he acted on it immediately, expanding the research department and in 1944 founding a student competition fund to draw scientific talent from colleges across the country ^[4]. The first payoff was an antihistamine, sold over the counter as Trimeton and by prescription as Chlor-Trimeton; by 1951 it had quadrupled the company's profits and pushed sales past $15 million ^[4][5].

The defining drama of Brown's tenure was the company's return to private hands. In 1951 the Attorney General put the government-owned firm up for sale, and on March 13, 1952, the Justice Department auctioned Schering's stock to a syndicate headed by Merrill Lynch, Pierce, Fenner & Beane for roughly $29 million; the syndicate then sold the shares to the public over 1952–1953 for about $31 million ^[2][4]. The new owners did not bring in their own man. They asked Brown, the lawyer who had run the place for the government, to stay on as president ^[4][5].

Then came the breakthrough that made Schering famous. In its Bloomfield, New Jersey, laboratories the microbiologist Arthur Nobile discovered that a bacterium could oxidize cortisone into a far more potent and better-tolerated anti-inflammatory steroid ^[6][7][8]. Schering brought it to market in 1955 as Meticorten (prednisone), followed by Meticortelone (prednisolone), corticosteroids so effective against arthritis, asthma, and inflammation that they became, in the trade's phrase, the envy of the industry ^[4][6][8]. Sales of the steroids reached nearly $46 million by the end of 1955 and topped $80 million by 1957 ^[4]. Brown plowed the proceeds back into research and a 1957 acquisition of White Laboratories, leaving behind a self-sustaining engine of innovation that produced Coricidin, Garamycin, and decades of growth ^[4][5].

Brown's was a conservative temperament, he reportedly turned down an offer from Revlon to sell Schering products as mass-market, high-volume items, distrustful of flashy consumer marketing ^[5]. He preferred to bet on the bench scientists and the slow compounding of discovery. As Schering's first American chief executive, he never invented a molecule, but he built the institution that did, and proved that the most valuable thing a leader can supply is not expertise in the product, but conviction about where value comes from ^[4][5].

Comparatively little is recorded of Francis C. Brown's origins, because he came to Schering not from the world of chemistry or commerce but from the machinery of the New Deal, and his public life effectively began there. By the 1930s he was a lawyer working inside the federal government's Depression-era institutions, joining the newly created Federal Deposit Insurance Corporation and serving as legal counsel to Leo T. Crowley, the FDIC's powerful chairman ^[4][5]. It was a lawyer's career, not a businessman's, and nothing in it pointed toward pharmaceuticals.

That changed by accident of war. When the United States moved to seize German-owned enterprises operating on American soil, Roosevelt turned to trusted administrators, and Crowley was appointed Alien Property Custodian with sweeping authority to vest and manage enemy property ^[3][4]. Schering Corporation, the American subsidiary of Berlin's Schering AG, with operations in New York and New Jersey, was among the most valuable prizes, its German directors ousted in January 1942 and its shares vested on April 18, 1942 ^[3][6]. Crowley needed a manager he could rely on for a company he could not afford to let fail, and he reached for his own counsel ^[4][5].

Brown was, by every account, the unlikeliest of choices: "a New Deal lawyer with no previous experience in the pharmaceutical business," as the company's own history would later put it ^[5]. He arrived as a custodian, not a builder, sent to keep a confiscated asset running until a permanent, qualified manager could be found ^[2]. The permanent manager was never needed. The caretaker became the chief executive, and the lawyer who knew nothing about drugs would run one of America's leading drug companies for nearly a quarter century ^[2][4].

Francis C. Brown's legacy is an institution rather than an invention. He took a company that existed only because the United States had confiscated it from a wartime enemy and, by betting consistently on research, turned it into one of the most admired drug houses in America, the firm that brought the world prednisone, a corticosteroid still on the World Health Organization's list of essential medicines ^[4][6][8]. The antihistamines, steroids, and antibiotics developed on his watch did not merely enrich shareholders; they reshaped the treatment of allergy, inflammation, and infection for millions of patients ^[4][6].

The company he built outgrew him. After Brown's departure in October 1966, Schering merged with Plough, Inc. in 1971 to form Schering-Plough, which went on to develop blockbusters such as the allergy drug Claritin before merging into Merck & Co. in 2009 ^[1][2]. The German parent, Schering AG, spent decades in litigation trying to reclaim the American name and business it had lost in 1942, a measure of how valuable the asset Brown stewarded had become ^[2].

Brown himself remains a near-anonymous figure, overshadowed by the chemists whose discoveries he funded and the famous brands he launched. But his story is one of the cleaner illustrations in business history of a single, simple truth: that leadership is less about mastering the craft than about knowing where the craft's value lies, and having the nerve to pour resources into it year after year, through war, confiscation, and three changes of ownership ^[2][4][5].